Ardana: On the way up

Why?,they were good with the same results as the previous trial.

"Teverelix LA, administered as a single subcutaneous injection, demonstrated symptomatic improvement from as early as week two and the duration of the effect appears to be in the order of 8 weeks based upon a preliminary analysis of the relevant clinical endpoint, the International Prostate Symptom Score (IPSS).

The study was a Phase II, randomised, double-blind, placebo-controlled study investigating the effects and safety of two different